Buy 3 AI-Powered Medical Stocks to Strengthen Your Portfolio in Q4
AI adoption is reshaping medical devices, with ISRG, TEM and TMO leveraging AI to advance precision medicine and drug development.
Zacks Investment Research9/24/2026Positive
TMO
Thermo Fisher Scientific IncNYSEHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$249.58B
P/E Ratio
36.37
EPS
$18.56
Beta
0.85
52W High
$682.98
52W Low
$434.50
50-Day MA
$601.62
200-Day MA
$539.69
Dividend Yield
0.27%
Profit Margin
15.00%
Forward P/E
24.15
PEG Ratio
1.98
About Thermo Fisher Scientific Inc
Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.
Fundamentals
| Revenue (TTM) | $46.34B |
| Gross Profit (TTM) | $18.99B |
| EBITDA | $11.74B |
| Operating Margin | 18.80% |
| Return on Equity | 13.50% |
| Return on Assets | 5.13% |
| Revenue/Share (TTM) | $123.89 |
| Book Value | $142.47 |
| Price-to-Book | 4.67 |
| Price-to-Sales (TTM) | 5.39 |
| EV/Revenue | 6.14 |
| EV/EBITDA | 23.62 |
| Quarterly Earnings Growth (YoY) | 9.40% |
| Quarterly Revenue Growth (YoY) | 10.50% |
| Shares Outstanding | $369.75M |
| Float | $368.82M |
| % Insiders | 0.13% |
| % Institutions | 94.09% |
Historical Volatility
HV 10-Day
24.30%
HV 20-Day
25.44%
HV 30-Day
24.83%
HV 60-Day
28.22%
HV Rank
27.4%
Volatility is currently contracting
Analyst Ratings
Consensus ($653.11 target)
3
Strong Buy19
Buy5
Hold1
Strong SellLatest News
Thermo Fisher Sees Stronger Demand, Calls 2026 an ‘Outstanding Year'
Thermo Fisher Scientific NYSE: TMO Chairman and Chief Executive Officer Marc Casper said the company is seeing improving demand across several end markets and expects 2026 to be an “outstanding year,” supported by stronger customer activity and operational execution.
MarketBeat9/17/2026Positive
Thermo Fisher Scientific Inc. (TMO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Thermo Fisher Scientific Inc. (TMO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha9/15/2026Neutral
Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus
Zacks spotlights Oportun Financial, Uranium Royalty and Amgen, alongside standout gains from its key stock portfolios.
Zacks Investment Research9/8/2026Positive
Should You Continue to Hold TMO Stock in Your Portfolio?
Thermo Fisher's growth is gaining momentum as acquisitions strengthen its life sciences reach, but macro risks and competition remain concerns.
Zacks Investment Research9/4/2026Positive
TMO Stock Could Gain Following the Launch of EMPAD G2 Detector
Thermo Fisher's EMPAD G2 detector enhances 4D STEM imaging speed, sensitivity and workflow integration, strengthening its Analytical Instruments portfolio.
Zacks Investment Research9/1/2026Positive
Thermo Fisher Scientific Introduces the Thermo Scientific™ EMPAD™ G2 Electron Detector to Advance Materials Research
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific™ EMPAD™ G2 detector, a new detector designed to help researchers see and understand materials in unprecedented detail. EMPAD G2 enables high-speed four-dimensional scanning transmission electron microscopy (4D STEM), an advanced form of electron microscopy that captures far more information about a material than a standard image, helping researchers better.
Business Wire8/27/2026Neutral
Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed the sale of its microbiology business to Astorg, a leading pan-European private equity firm, for consideration of approximately $1.075 billion, consisting of cash and a $50 million seller note. The microbiology business provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food safety testing.
Business Wire8/12/2026Neutral
Thermo Fisher Raises 2026 Outlook After Strong Second-Quarter Results
Thermo Fisher Scientific Inc. TMO raised its 2026 outlook after second-quarter earnings and revenues exceeded expectations. The update reflects stronger customer activity, better acquisition performance and improved operating leverage.
Zacks Investment Research8/3/2026Positive
Unlocking Thermo Fisher (TMO) International Revenues: Trends, Surprises, and Prospects
Examine the evolution of Thermo Fisher's (TMO) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Zacks Investment Research8/3/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TMO and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/28/2026